The Drug Development Institute (DDI) is a biotech-like institute embedded in The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). By bringing an industry-focused perspective to all investment and management decisions, the DDI ensures that programs have a high likelihood of progressing to clinical stage development. Our goal is to rapidly translate Ohio State’s most innovative research into tomorrow’s most promising treatments for patients with cancer. The DDI employs a combination of targeted investments, strategic management and cutting-edge drug development resources to drive projects from discovery through early drug development, thus creating high-value new drug candidates. The DDI Pipeline: Research: The DDI leverages world-class research and drug development resources at The Ohio State University to advance projects from early drug discovery through preclinical and clinical development. Advisory Board: The DDI Advisory Board consists of internationally recognized experts with proven track records in pharmaceutical drug discovery, development and commercialization. Partnerships with Industry and Venture Capitalist Firms: DDI partners with pharmaceutical, biotech and venture capital companies to bridge the gap between drug discovery and early clinical development, accelerating development timelines and delivering innovative treatments to patients sooner.